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The importance of immunoregulatory T cells has become increasingly apparent. Both 
CD4
 
 
 
CD25
 
 
 
 T cells and CD1d-restricted NKT cells have been reported to down-regulate 
tumor immunity in mouse tumor models. However, the relative roles of both T cell 
populations have rarely been clearly distinguished in the same tumor models. In addition, 
CD1d-restricted NKT cells have been reported to play a critical role not only in the down-
regulation of tumor immunity but also in the promotion of the immunity. However, the 
explanation for these apparently opposite roles in different tumor models remains unclear. 
We show that in four mouse tumor models in which CD1d-restricted NKT cells play a role in 
suppression of tumor immunity, depletion of CD4
 
 
 
CD25
 
 
 
 T cells did not induce enhancement 
of immunosurveillance. Surprisingly, among the two subpopulations of CD1d-restricted NKT 
cells, V
 
 
 
14J
 
 
 
18
 
 
 
 (type I) and V
 
 
 
14J
 
 
 
18
 
 
 
 (type II) NKT cells, type I NKT cells were not 
necessary for the immune suppression. These unexpected results may now resolve the 
paradox in the role of CD1d-restricted NKT cells in the regulation of tumor immunity, in 
that type II NKT cells may be sufficient for negative regulation, whereas protection has been 
found to be mediated by 
 
 
 
-galactosylceramide–responsive type I NKT cells.
 
Although cancer vaccines and immunotherapy
have become more successful at inducing CTL
responses specific for the tumor, a remaining
hurdle is to translate this success into actual
tumor regression. It has come to light in recent
years that a major reason that CTL activity
measurable in vitro does not cause tumor re-
gression in vivo is the existence of negative
regulatory mechanisms inhibiting the CTL
response. These include negative regulatory
molecules on the T cells themselves, such as
CTL antigen–4 (1) and program death–1 (2),
as well as regulatory cells. In this context, there
has been much interest in the CD4
 
 
 
CD25
 
 
 
 T
regulatory (T reg) cell (3, 4). However, there
are other immunoregulatory cells, including
CD1d-restricted NKT cells (5, 6), myeloid
suppressor cells (7, 8), and M2 macrophages
(9, 10). Although all of these cells may con-
tribute to the failure of vaccine-induced T
cells to destroy tumors, little is understood
about the relative importance of these different
mechanisms.
NKT cells are a unique T cell subset ex-
pressing both TCR and NK cell receptors.
Most NKT cells are restricted by the MHC class
I–like molecule CD1d. These CD1d-restricted
NKT cells are known to include two subsets:
the better characterized, more widely studied
one expressing the canonical TCR, V
 
 
 
14J
 
 
 
18
(type I) NKT cells, and a less well character-
ized one of non-V
 
 
 
14J
 
 
 
18 (type II) NKT
cells (11). In the mouse, most CD1d-restricted
NKT cells are CD4
 
 
 
 and the rest are CD4
 
 
 
CD8
 
 
 
. CD1d-restricted NKT cell function
has been implicated in several tumor models
(12). Activation of the type I NKT cells by ad-
ministration of its strong agonist 
 
 
 
-galactosyl-
ceramide (
 
 
 
-GalCer) is beneficial in several
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experimental tumor models, especially in preventing meta-
static growth (13, 14).
Besides their ability to mediate antitumor effects, type I
NKT cells enhance natural immunosurveillance in the absence
of exogenously added ligands. In the TC-1 tumor model, type
I NKT cells were beneficial in stimulating early adaptive im-
munity to tumor cells (15). In a methylcholanthrene-induced
sarcoma model, type I NKT cells play a role in tumor immuno-
surveillance, as J
 
 
 
18 KO mice—which specifically lack type
I NKT cells—develop sarcomas faster than their wild-type
counterparts. Tumors arising in methylcholanthrene-treated
J
 
 
 
18 KO mice were rejected in a type I NKT cell–dependent
manner when transplanted into wild-type hosts (16), and adop-
tive transfer of type I NKT cells into J
 
 
 
18 KO mice provided
potent protection against these tumors (17).
In contrast, it has also been reported that CD1d KO
mice—which lack CD1d-restricted NKT cells—have height-
ened immunity to tumors (18). The fibrosarcoma 15-12RM,
which shows spontaneous regression, after initial growth of the
tumor followed by recurrence in wild-type mice, failed to re-
cur in CD1d KO mice (5). CD1d KO mice also developed
fewer tumor nodules in the lungs than wild-type mice when
the syngeneic tumor CT26 was injected i.v. (19). In these tu-
mor models, a negative regulatory NKT cell was found to ini-
tiate a novel regulatory circuit involving IL-13, myeloid cells,
and TGF-
 
 
 
 (6). Likewise, CD1d KO mice were considerably
more resistant to spontaneous 4T1 tumor metastases than wild-
type mice in a post-surgery setting (20). These contrasting re-
sults define a paradox in which NKT cells appear to both pro-
tect against tumors and inhibit tumor immunosurveillance.
We found that depletion of CD4
 
 
 
 T cells in several of
these tumor models removed a regulatory cell and thereby al-
lowed CD8-mediated immunosurveillance to prevent tumor
recurrence or metastases. We identified one such regulatory
cell as a CD4
 
 
 
 CD1d-restricted NKT cell that was absent in
CD1d KO mice. However, those studies did not exclude the
possible additional role of the T reg cell that has also been
shown to suppress tumor immunity (3, 4). We also did not
examine the role of CD1d in this process and could not fur-
ther characterize the nature of the regulatory NKT cell be-
cause of the lack of tools, such as J
 
 
 
18 KO mice on the
BALB/c background, and little appreciation of the existence
or function of type II NKT cells in normal mice at the time
 
Figure 1. T reg cells are not necessary for down-regulation of 
tumor immunosurveillance.
 
 (A) 10
 
6 
 
15-12RM tumor cells were injected 
subcutaneously into BALB/c mice on day 0. 1 mg anti-CD25 (PC61; closed 
squares) or control rat IgG (open diamonds) was injected i.v. on days 
 
 
 
4 
and 
 
 
 
2. 500 
 
 
 
g anti-CD4 (GK1.5; closed circles) was injected i.p. on days 
0, 1, 2, 6, and 10. The results are representative of two experiments (
 
n
 
 
 
 
 
 5). 
(B) T reg cell depletion is effective against subcutaneous CT26 but not 
CT26-L5 variant tumors. Mice challenged subcutaneously with 10
 
4
 
 CT26 or 
CT26-L5 cells were given 1 mg PC61 i.p. on days 
 
 
 
4 and 
 
 
 
1 of tumor 
challenge. 
 
n
 
 
 
 
 
 5 for all groups except those receiving control Ig, in which 
 
n
 
 
 
 
 
 4. Mice were culled when tumors exceeded 1 cm in diameter, and 
data are represented as percent survival. (C) 5 
 
 
 
 10
 
5 
 
CT26 tumor cells 
were injected i.v. into BALB/c mice on day 0. 1 mg anti-CD25 was injected 
i.v. on days 
 
 
 
5 and 
 
 
 
3. On day 14 or 15, mice were killed and pulmonary 
tumor metastases were enumerated. CD1d KO mice had a significantly 
smaller number of metastases (P 
 
 
 
 0.002 by one-way ANOVA). The results 
are pooled from two independent experiments, and additional results 
from these experiments are shown in Fig. 4 C. The horizontal lines indicate 
the means. 
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(21, 22). We have therefore now examined several tumor
models in which this NKT regulatory cell plays a role to de-
termine (a) whether the T reg cell also inhibits immunosur-
veillance in these systems, (b) whether the CD1d molecule
must present antigen to activate the regulatory cell or is simply
required for NKT cells to develop during ontogeny, and (c)
whether the regulatory NKT cell is the same as the type I
NKT cell (
 
 
 
-GalCer responsive) that has also been shown to
protect against tumors or is a different, type II NKT cell that
does not respond to 
 
 
 
-GalCer.
 
RESULTS AND DISCUSSION
T reg cells are not necessary for down-regulation of 
tumor immunosurveillance
 
We began by examining the role of T reg cells in down-regula-
tion of immunosurveillance in tumor models in which CD1d-
restricted NKT cells have been shown to play a critical role
in immune suppression. Four different mouse tumor models—
the subcutaneous 15-12RM fibrosarcoma, the subcutaneous
CT26-L5 colon carcinoma, the 4T1 mammary carcinoma in-
oculated in the mammary gland, and the lung metastases of the
CT26 colon carcinoma inoculated i.v.—were used in our sev-
eral laboratories. Syngeneic BALB/c mice were treated with
anti-CD25 antibody before tumor challenge (Fig. 1). In the
subcutaneous tumor models, 15-12RM and CT26-L5, deple-
tion of T reg cells had no impact on tumor growth, whereas
CD4 depletion reduced tumor growth (Fig. 1, A and B). In
contrast, as previously reported (23), anti-CD25 treatment was
effective against subcutaneous parental CT26 in a side-by-side
comparison with the CT26-L5 variant (which also serves as a
positive control for the efficacy of anti-CD25 treatment; Fig. 1
B). The failure to observe a role for T reg cells in the CT25-L5
model may be caused by differences in the tumor lines. This
idea is supported by the fact that the CT26 grows in CD1d KO
mice in which the CT26-L5 does not grow (Fig. 4 B; unpub-
lished data). In the CT26 lung metastasis model, we also could
not see any effect of anti-CD25 treatment on the number of
lung metastases (Fig. 1 C). We confirmed that these results were
not caused by the failure of T reg cell depletion by observing
that only 
 
 
 
0.12% of spleen cells were CD25
 
 
 
 even 13 d after
the final treatment with anti-CD25 (Fig. S1, available at http://
www.jem.org/cgi/content/full/jem.20051381/DC1). Al-
though depletion of T reg cells had no effect on CT26 me-
tastases, the absence of NKT cells in CD1d KO mice led to a
reduced number of metastases (P 
 
 
 
 0.002) in this tumor model
(Fig. 1 C), as we previously observed (19). Together with our
previous observations that anti-CD25 treatment had no effect
on primary growth or metastases of the 4T1 tumor (20), these
results suggest that T reg cells are not necessary for down-regu-
lation of immunosurveillance in any of those tumor models.
 
Activation of NKT cells through CD1d is necessary for 
down-regulation of tumor immunosurveillance
 
We and others have shown that NKT cell–deficient CD1d
KO mice are highly resistant to tumor growth (Fig. 1 C) (5,
18–20). CD1d may simply be necessary during ontogeny for
NKT cell development or may also be necessary to induce
immunoregulatory activity of NKT cells. To confirm that the
resistance observed in CD1d KO mice is not a result of any
defects, besides the lack of NKT cells, caused by genetic dis-
ruption of the 
 
cd1d
 
 gene and to test whether CD1d is neces-
sary to activate NKT cells to display regulatory activity, we
blocked antigen presentation by a nondepleting anti-CD1d
antibody in vivo in the 15-12RM tumor model (Fig. 2). Al-
though the treatment did not completely protect mice from
tumor recurrence, the mice were significantly protected (P 
 
 
 
0.05). Thus, NKT cells need to be activated through CD1d to
down-regulate tumor immunosurveillance.
To exclude the possibility that suppression of tumor
growth in CD1d KO mice is simply the result of CD1d on
tumor cells acting as a rejection antigen, we also examined
the expression of CD1d. CD1d could not be detected on the
surface of any of the tumors used by flow cytometry (Fig. 3
A), and immunohistochemical analysis of tissue sections from
CT26-L5 tumors failed to detect CD1d expression in vivo
(Fig. 3 B). Thus, inhibition of tumor growth in CD1d KO
mice is unlikely to be caused by an immune response to the
CD1d antigen. Although immunolabeling techniques might
not detect extremely low levels of CD1d, the conclusion
that CD1d is not simply acting as a rejection antigen is also
supported by the protection afforded by anti-CD1d antibody
in wild-type BALB/c mice (Fig. 2), which cannot be ex-
plained by lack of tolerance to CD1d, and by the enhance-
ment of tumor rejection by CD4 depletion but not CD25
 
 
 
T reg cell depletion.
 
Non-V
 
 
 
14J
 
 
 
18
 
 
 
 (type II) NKT cells in the absence of 
V
 
 
 
14J
 
 
 
18
 
 
 
 (type I) NKT cells are sufficient for 
down-regulation of tumor immunosurveillance
 
The ability of CD1d KO mice and of blockade of CD1d to
spontaneously suppress tumor growth in multiple tumor
Figure 2. Antigen presentation by CD1d is necessary for down-
regulation of tumor immunosurveillance. 106 15-12RM tumor cells 
were injected into BALB/c mice subcutaneously on day 0. 200  l anti-
CD1d ascites (closed circles) was injected i.v. every other day for 1 wk from 
day 0. 500  g anti-CD4 (open triangles) was injected i.p. on days 0, 1, 2, 6, 
and 10. P   0.05 by log-rank test between control and anti-CD1d–treated 
or anti-CD4–treated groups. The results are representative of two experi-
ments (n   5). 
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models suggested that a CD1d-dependent mechanism sup-
pressed the generation of effective antitumor immune re-
sponses to some tumors. As the most obvious defect in
CD1d KO mice is the lack of V
 
 
 
14J
 
 
 
18
 
 
 
 (type I) NKT
cells, we investigated the role of these cells in down-regula-
tion of tumor immunosurveillance by growing four different
tumors—15-12RM, 4T1, CT26, and CT26-L5—in J
 
 
 
18
KO mice, which specifically lack type I NKT cells but ex-
Figure 3. Tumor cell lines do not express CD1d in vitro or in situ. 
(A) 15-12-CD1d (CD1d-transfected positive control), 15-12RM, CT26, 4T1, 
and CT26-L5 tumor cell lines and spleen cells of CD1d KO mice (negative 
control) were stained with FITC-labeled anti-CD1d mAb and analyzed by 
flow cytometry. Shaded graphs indicate cells stained with isotype-
matched control antibody; red and bold lines indicate cells stained with 
anti-CD1d antibody. (B) Frozen sections of subcutaneous CT26-L5 tumors 
(b, d, and f) or spleens (a, c, and e) were stained with control IgG (a and b), 
anti-CD1d (c and d), or anti-CD11b (e and f). The sections were counter 
stained with hemotoxylin ( 100).
Figure 4. V 14J 18  (type I) NKT cells are not necessary for down-
regulation of tumor immunosurveillance. (A) The wild-type (open 
diamonds), CD1d KO (closed triangles), and J 18 KO (closed circles) BALB/c 
mice were injected subcutaneously with 106 15-12RM tumor cells on day 0, 
and tumor size was monitored over time. P   0.05 by log-rank test between 
CD1d KO and wild-type or J 18 KO mice. The results are representative of 
two experiments (n   5). (B) The wild-type, CD1d KO, and J 18 KO BALB/c 
mice were inoculated subcutaneously with 104 CT26-L5 cells and subse-
quently monitored for survival (n   5). Data are representative of two 
experiments. (C) The wild-type, CD1d KO, and J 18 KO BALB/c mice were 
injected i.v. with 5   105 CT26 cells. After 14 d, pulmonary metastases were 
enumerated. In one group, mice were treated with PC61 as in Fig. 1 C. CD1d 
KO mice had significantly fewer metastases (P   0.002 by one-way ANOVA). 
The results are pooled from two independent experiments. The horizontal 
lines indicate the means. The data in Fig. 4 C and in Fig. 1 C were all obtained 
within the same larger experiments. 
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press CD1d (Fig. 4). Surprisingly, in contrast to CD1d KO
mice, growth of 15-12RM (Fig. 4 A) and CT26-L5 (Fig. 4
B) tumors in J
 
 18 KO mice was similar to that in wild-type
mice. J 18 KO mice also developed  250 lung metastases
in the CT26 lung metastasis model, which was comparable
to levels seen in wild-type mice, whereas CD1d KO mice
developed significantly fewer metastases (P   0.002; Fig. 4
C). In the 4T1 model, there was no apparent difference in
the size of primary tumors among wild-type, CD1d KO,
and J 18 KO mice (Fig. 5 A). However, CD1d KO mice
showed a significantly higher (P   0.02) survival rate after
surgical removal of primary tumors compared with wild-
type BALB/c mice. In this model, J 18 KO mice showed
significantly shorter (P   0.02) survival than the CD1d KO
mice in all three experiments even though they also had
greater survival than wild-type mice in two of three experi-
ments, suggesting that in this model type I NKT cells also
may play some role in the suppression (Fig. 5 B). These re-
sults demonstrated that type I NKT cells were not necessary
for down-regulation of tumor immunosurveillance against
these tumors and that type II NKT cells may be sufficient for
complete or partial suppression, whereas type I NKT cells
may play a minor role in the 4T1 mammary carcinoma. The
difference in the role of type I NKT cells in the 4T1 model
may be partly caused by the use of different cytokines and a
different mechanism downstream of NKT cells to suppress
tumor immunity compared with the 15-12RM and CT26
tumors (9, 20).
We further examined the role of T reg cells in the ab-
sence of type I NKT cells in the CT26 lung metastasis
model. J 18 KO mice were treated with PC61 mAb before
the tumor challenge as in Fig. 1. The depletion of CD4 
CD25  cells in J 18 KO mice did not affect the develop-
ment of pulmonary metastases (Fig. 4 C), just as we observed
in wild-type mice. Thus, in the absence of both type I NKT
cells and T reg cells, type II NKT cells are sufficient to sup-
press immunosurveillance.
Differences between the two types of CD1d-restricted
NKT cells have been reported (21, 22, 24). In autoimmune
disease, graft rejection, and allergy, type I NKT cells have
been found to be immunosuppressive (25, 26), whereas in
hepatitis (27) and colitis (28), type II NKT cells have been
implicated in tissue destructive processes. However, their
functional difference in regulation of tumor immunity was
unknown. We showed that type II NKT cells were suffi-
cient to suppress tumor immunosurveillance in multiple
mouse tumor models. There are two possible explanations
for these results. First, either type II or type I NKT cells are
each sufficient for down-regulation of tumor immunosur-
veillance. Thus, eliminating either population alone will not
Figure 5. V 14J 18  (type I) NKT cells are not necessary for 
down-regulation of tumor immunosurveillance against lung 
metastases of 4T1 breast tumors, and primary tumors are not affected 
by CD1d-restricted NKT cells. (A) The wild-type (open diamonds), J 18 
KO (closed circles), and CD1d KO (closed triangles) BALB/c mice were 
inoculated in the mammary gland on day 0 with 7,000 4T1 tumor cells, 
and mice were followed for primary tumor growth. Data are from seven 
J 18 KO, seven wild-type, and three CD1d1 KO mice. (B) The wild-type 
(open diamonds), CD1d KO (closed triangles), and J 18 KO (closed circles) 
BALB/c mice were injected with 7,000 4T1 cells in the mammary fat pad. 
Primary 4T1 tumors were surgically removed 14 d after tumor injection, 
and mice were subsequently monitored for survival. In all three experi-
ments, CD1d KO mice survived significantly longer than wild-type and 
J 18 KO mice (P   0.02 by log-rank test). In experiments 1 and 3, J 18 KO 
mice survived significantly longer than wild-type mice (P   0.02).TYPE II NKT CELLS REGULATE TUMOR IMMUNITY | Terabe et al. 1632
relieve the immune suppression. Second, type II NKT cells
are the primary type of NKT cell that regulates immunosur-
veillance to induce immune suppression. Existing reagents
do not allow these two possibilities to be distinguished be-
cause there are no unique markers identified for type II
NKT cells. Also, recent findings in inflammatory bowel dis-
ease suggest that human type II NKT cells can make IL-13
(28). Thus, the findings we report in this paper reconcile
previous observations ascribing opposing functions in tumor
immunity to the same NKT cells and, thus, may resolve an
apparent paradox. Furthermore, these experiments also iden-
tify an important regulatory cell that operates in tumor mod-
els in which the T reg cell plays little or no role.
MATERIALS AND METHODS
Mice. Inbred BALB/c mice were purchased from the Frederick Cancer
Research Facility or the Walter and Eliza Hall Institute of Medical Research
or bred in the University of Maryland, Baltimore County animal facility
from stock mice obtained from the Jackson Laboratory. BALB/c CD1d-
deficient mice (CD1d KO mice; provided by M. Grusby, Harvard University,
Boston, MA or by L. van Kaer, Vanderbilt University, Nashville, TN) and
BALB/c J 18-deficient mice (J 18 KO mice; provided by M. Taniguchi
and T. Nakayama, Chiba University, Chiba, Japan or by D. Umetsu, Stan-
ford University, Stanford, CA) were bred at the National Cancer Institute,
the Peter MacCallum Cancer Centre, and the University of Maryland. All
gene-targeted mice were backcrossed onto the BALB/c background for 10
generations and genotyped by both PCR and flow cytometry. Mice  6 wk
old were used in all experiments. Female mice were used for experiments
with the 4T1 tumor. All animal experiments were approved by the Animal
Care and Use Committee of the National Cancer Institute, the Peter Mac-
Callum Cancer Centre, or the University of Maryland, Baltimore County.
Antibodies. Purified mAbs reactive with mouse CD4 (GK1.5; American
Type Culture Collection) and CD25 (PC61; American Type Culture Col-
lection) were purified from ascites by Harlan Bioproducts for Science, Inc.
Ascites of anti–mouse CD1d (3C11) was provided by J. Yewdell (National
Institute of Allergy and Infectious Diseases, Bethesda, MD).
Tumor cell lines. The fibrosarcoma line 15-12RM (29) was maintained
in RPMI 1640 with 10% FCS, penicillin/streptomycin, nonessential amino
acids,  L-glutamine, and 200  g/ml of G418. The colon carcinoma line
CT26 was maintained in RPMI 1640 with 10% FCS, penicillin/streptomy-
cin, nonessential amino acids, and L-glutamine. The mammary carcinoma
line 4T1 was maintained in IMDM with 10% FCS, penicillin/streptomycin,
and L-glutamine. The carcinogen-induced colon carcinoma line Colon-26
(CT26-L5) was a gift from I. Saiki (Toyama Medical and Pharmaceutical
University, Toyama, Japan) and was maintained in RPMI 1640 with 5%
FCS, penicillin/streptomycin, and L-glutamine.
In vivo tumor assays. Single cell suspensions of tumor cells were pre-
pared in PBS and injected either in the mammary fat pad, subcutaneously or
i.v., as indicated in the figures. In various groups of mice, CD4  cells were
depleted by injecting 500  g anti-CD4 mAb (clone GK1.5). The antibody
was administered i.p. as indicated in the figures. CD25  cells were depleted
by i.p. administration of anti-CD25 mAb (500  g or 1 mg; clone PC61) as
indicated in the figures, which was previously shown to be sufficient to de-
plete all CD4 CD25  cells in the spleen (as determined by flow cytometry).
Staining of lungs to enumerate CT26 tumor nodules and surgical removal of
primary 4T1 tumors was performed as previously described (19, 30).
In vivo staining of CD1d. Tumor and spleen samples were harvested
and snap frozen in OCT compound and stored at  80 C until processing.
6- m tissue sections were cut on a cryostat (CM 3050 S; Leica), fixed for
10 min in ice-cold acetone, and rehydrated in PBS   1% BSA for 20 min.
Sections were washed twice, and Fc receptors were blocked by incubation
with 2.4G2 for 30 min. Blocked sections were then stained with biotiny-
lated anti-CD1d (clone 1B1), anti-CD11b (clone M1/70), or rat IgG iso-
type control (all purchased from BD Biosciences) for 2 h at 4 C. After incu-
bation with primary antibodies, sections were washed three times and
endogenous peroxidase activity was blocked by incubation in 0.3% H2O2 in
PBS. After washing, biotinylated antibody staining was visualized by the
StreptABComplex/HRP and Liquid DAB  Substrate Chromogen System
(both from DakoCytomation) according to the manufacturer’s instructions.
Sections were counterstained with hemotoxylin.
Statistical analysis. The Mann-Whitney U rank sum test, one-way anal-
ysis of variance (ANOVA), or log-rank test were used for the statistical anal-
ysis of data. p-values  0.05 were considered significant.
Online supplemental material. Fig. S1 shows that the depletion effect
of anti-CD25 persists for at least 13 d. Online supplemental material is avail-
able at http://www.jem.org/cgi/content/full/jem.20051381/DC1.
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